Clinical Trials Browser

Lethal Congenital Contracture Syndrome 2, Fibromatosis, Gingival, 2, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Prostatic Neoplasms, Castration-Resistant, Triple Negative Breast Neoplasms

NCT04471974 2025-07-22

ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Phase 2 Active not recruiting

61 enrolled

Genitourinary

Prostatic Neoplasms

NCT02446444 2025-05-30

ENZARAD

Phase 3 Active not recruiting

802 enrolled

Genitourinary

Prostatic Neoplasms

NCT06312670 2025-05-29

Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer

Phase 2 Completed

13 enrolled

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT03300505 2025-05-13

ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer

Phase 1 Terminated

9 enrolled 14 charts

Genitourinary

Prostatic Neoplasms

NCT02278185 2025-05-11

Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer

Phase 2 Completed

19 enrolled 18 charts

Genitourinary

Prostatic Neoplasms

NCT04332744 2025-05-11

ZZ-First

Phase 2 Completed

54 enrolled

Genitourinary

Prostatic Neoplasms

Clinical Trials

Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

PREDICT

Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer

A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.

Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

ARCH

Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer

Tivozanib + Enzalutamide in Adv Prostate Cancer

Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer

Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression

Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer

CASPAR

A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer

FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)

Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

STEEL

DIVINE

PROSTEP-002

Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer

Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide

Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer

Combination Study of Antibiotics With Enzalutamide (PROMIZE)

Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer

Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Testosterone Therapy in Castration Resistant Prostate Cancer

ARACOG

TALENT

Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy

Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial

Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer

The COSMYC Trial (COmbined Suppression of MYC)

Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer

FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer

PROTRACT

Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer

A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours

ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

ENZARAD

Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer

ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer

Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer

ZZ-First